Drug company Johnson & Johnson has agreed to pay a settlement of more than $2.2 billion in response to accusations of improper and illegal marketing of Risperdal, the company’s bestselling antipsychotic drug. According to The New York Times, the agreement, which includes both criminal and … Full Story
The growing concern with the large pharmaceutical companies is because of the influence exercised over safety regulations in pursuit of financial gain instead of patient safety. The worlds second biggest maker of medical products, Johnson & Johnsons, manufactures a schizophrenia drug Risperdal® which has annual global sales of $2.1 billion. While a J&J spokesperson claimed an update to the Risperdal® label is indeed being made, and we will be sending out letters to health care professionals soon, the company had already issued Risperdal® warning letters to Canadian doctors and pharmacists six months before announcing Risperdal® side effect risks in the U.S.
Clinical trials testing Risperdal® in Alzheimer patients heightened concerns that the occurrence of serious Risperdal® side effects is higher than previously thought. Among 764 Risperdal® patients, 29 cases of stroke and stroke-related events were seen, in addition to four deaths. A Public Citizen consumer watchdog group pharmacist and research analyst thinks that the recent Risperdal® studies should push U.S. regulators to examine more deeply if younger aged schizophrenia patients are also more prone to experiencing Risperdal® stroke and other side effects of Risperdal®.
Approved in the 1990s as a type of new atypical anti-psychotic drug and thought to initially have fewer unwanted side effects, Risperdal® uses upon approval only included schizophrenia treatment. Risperdal® is often prescribed to control behavioral disorders in elderly patients with dementia and Alzheimers disease, including delusions, aggression, and anxiety, but the recent Risperdal® stroke announcement shows there is an increased risk in prescribing Risperdal® to a wider range of patients.
Public Citizen consumer watchdog group pharmacist and research analyst Larry Sasich thinks, The Risperdal® label clearly states that there is no evidence this drug is safe or effective in treating dementia, and it looks like doctors are hurting people by prescribing it for this condition. Risperdal® labeling changes will be implemented according to J&J to more accurately warn of the increased risk of Risperdal® stroke and other Risperdal® side effects that can include blood clots, hemorrhages, and death.
For more information on Risperdal® side effects please contact us to confer with a Risperdal® lawyer.
Johnson & Johnson (J&J), under investigation for its marketing practices of the anti-psychotic medication Risperdal®, said it will pay up to $2 billion to settle the inquiry. The Wall Street Journal (WSJ) carried the news story Thursday. The article said a $400 million criminal fine … Full Story